2015—2017年解放军第174医院门诊抗高血压药的使用情况分析

Analysis on utilization of anti-hypertensive drugs in No.174 Hospital of PLA from 2015 to 2017

目的分析解放军第174医院门诊抗高血压药的使用情况,为临床合理用药提供参考。方法对解放军第174医院门诊2015—2017年抗高血压药品的使用数量、用药金额及用药频度(DDDs)、日均费用(DDC)以及序号比(B/A)进行统计分析。结果 2017年抗高血压药的使用金额有所下降,所占药品总使用金额的比例也有所下降。钙通道阻滞剂(CCB)、血管紧张素Ⅱ受体拮抗剂(ARB)的用药金额始终排在前两位,利尿剂的用药金额排在最后1位。苯磺酸氨氯地平片、美托洛尔缓释片、贝那普利片、缬沙坦氨氯地平片(I)、氯沙坦钾片和吲达帕胺缓释片的用量呈逐年上升趋势,坎地沙坦酯片、厄贝沙坦氢氯噻嗪片、厄贝沙坦片和美托洛尔片的用量呈逐年下降趋势,苯磺酸左旋氨氯地平片、苯磺酸氨氯地平片、美托洛尔缓释片和坎地沙坦酯片的用量一直排在前列。苯磺酸左旋氨氯地平片、苯磺酸氨氯地平片、硝苯地平控释片以及缬沙坦胶囊的用药金额一直排在前列。呋塞米片、卡托普利片、硝苯地平片和氢氯噻嗪片的用药金额排序居后。磺酸左旋氨氯地平片、苯磺酸氨氯地平片、硝苯地平控释片、坎地沙坦酯片和美托洛尔缓释片的DDDs一直排在前位,显示较高的使用频率;吲达帕胺缓释片、美托洛尔片、卡托普利片、硝苯地平片和氢氯噻嗪片的使用频率比较低。缬沙坦胶囊的DDC居首位,坎地沙坦酯片次之。2015年坎地沙坦酯片,2016年缬沙坦氨氯地平片(I),2015、2016年卡托普利片、硝苯地平片,2015—2017年苯磺酸左旋氨氯地平片的B/A均为1.00,同步性较好,其余均有偏倚。结论解放军第174医院门诊口服抗高血压品种比较齐全,用药可选性比较大,CCB和ARB是主要的使用品种,符合抗高血压药的用药原则,选择药物时,要考虑安全性还要考虑用药的经济性,切实减轻患者的经济负担。

Objective To analyze the utilization of Anti-hypertensive drugs in No. 174 Hospital of PLA from 2015 to 2017, and provide a reference for clinical rational drug use. Methods The consumption quantity, consumption sum, defined daily dose system（DDDs）, defined daily cost（DDC）, and drug sequence ratio（B/A） in No. 174 Hospital of PLA from 2015 to 2017 were calculated and compared. Results Total consumption sum of Anti-hypertensive drugs and the proportion of the total amount of medicines were declined in 2017. Consumption sum of Calcium channel blockers（CCB） and angiotensin Ⅱ receptor antagonist（ARB） always ranked in the top two, while the amount of diuretics medication was in the last place. The amount of Amlodipine Besylate Tablets, Metoprolol Sustained-release Tablets, Benazepril Tablets, Valsartan Amlodipine Tablets（I）, Iosartan Potassium Tablets and Sustained-release Tablets of indapamide was increased year by year, while the amount of Candesartan Ciprofeta Tablets, Irbesartan Hydrochlorothiazide Tablets, Irbesartan Tablets, and Metoprolol Tablets showed a declining trend. The amount of Levamlodipine Besylate Tablets, Amlodipine Besylate Tablets, Metoprolol Sustained-release Tablets and Candesartan Cilexetil Tablets had been ranked in the forefront. Consumption sum of Levamlodipine Besylate Tablets, Amlodipine Besylate Tablets, Nifedipine Controlled-released Tablets, and Valsartan Capsules were ranked in the first palce, while consumption sum of Furosemide Tablets, Captopril Tablets, Nifedipine Tablets, and Hydrochlorothiazide Tablets were in the last place. DDDs of Levamlodipine Sulfonate Tablets, Amlodipine Besylate Tablets, Nfedipine Controlled-release Tablets, Candesartan Cilexetil Tablets, and Metoprolol Sustained-release Tablets have been ranked in the first place, showing more High frequency of use. DDDs of Indapamide Extended Sustained-release Tablets, Metoprolol Tablets, Captopril Tablets, Nifedipine Tablets, and Hydrochlorothiazide Tablets were relatively low. DDC of Valsartan Capsules was the highest, followed by Candesartan Cilexetil Tablets. B/A of Candesartan Cilexetil Tablets in 2015, Valsartan amlodipine tablets（I） in 2016, Captopril tablets and Nifedipine tablets in 2015 and 2016, Levamlodipine Besylate Tablets from 2015 to 2017 were equal to 1.00, showing synchronization was better, while the rest were biased. Conclusion The oral anti-hypertensive variety in No. 174 Hospital of PLA was relatively complete, and medication selectivity was relatively large, and CCB and ARB were the main varieties, in line with the hypertensive drug treatment principles. When choosing a drug, the safety and the economy of medication should be considered to effectively reduce the financial burden on patients.